Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review

Mantle Cell Lymphoma

Ben-Niklas Baermann  1 , Sascha Dietrich  1
Anna Sureda  1 , Selim Corbacioglu  2 , Raffaella Greco  3 , Nicolaus Kröger  4 , Enric Carreras  5
, editors.
In: The EBMT Handbook: Hematopoietic Cell Transplantation and Cellular Therapies [Internet]. 8th edition. Cham (CH): Springer; 2024. Chapter 87.
.
Affiliations
Free Books & Documents
Review

Mantle Cell Lymphoma

Ben-Niklas Baermann et al.
Free Books & Documents

Excerpt

Mantle cell lymphoma (MCL) is an aggressive B-cell lymphoma, which is characterized by the chromosomal translocation t(11;14)(q13;q32) and overexpression of cyclin D1 in the vast majority of cases. Most patients present with advanced stage disease often with extra-nodal dissemination. High Ki67 proliferation index (Hoster et al. 2016), blastoid histologic variant (Bernard et al. 2001), and TP53 mutations represent high-risk features at diagnosis (Eskelund et al. 2017).

PubMed Disclaimer

References

    1. Bernard M, Gressin R, Lefrere F, Drenou B, Branger B, Caulet-Maugendre S, Lamy T. Blastic variant of mantle cell lymphoma: a rare but highly aggressive subtype. Leukemia. 2001;15(11):1785–91. https://doi.org/10.1038/sj.leu.2402272. - DOI - PubMed
    1. Cheah CY, Seymour JF, Wang ML. Mantle cell lymphoma. J Clin Oncol. 2016;34:1256–69. - PubMed
    1. Cook G, Smith GM, Kirkland K, et al. Outcome following reduced-intensity allogeneic stem cell transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2010;16:1419–27. - PubMed
    1. Dietrich S, Tielesch B, Rieger M, et al. Patterns and outcome of relapse after autologous stem cell transplantation for mantle cell lymphoma. Cancer. 2011;117:1901–10. - PubMed
    1. Dietrich S, Boumendil A, Finel H, et al. Outcome and prognostic factors in patients with mantle-cell lymphoma relapsing after autologous stem-cell transplantation: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT). Ann Oncol. 2014a;25:1053–8. - PubMed
Further Reading
    1. Dreger P, Michelet M, Bosman P, et al. Ibrutinib for bridging to allogeneic stem cell transplantation (alloHCT) in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) is safe and effective update results of a study by the EBMT chronic malignancy and the lymphoma working parties, the French Cooperative Group for CLL and the Société Française de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC). Bone Marrow Transplant. 2018;54:44. https://doi.org/10.1038/s41409-018-0207-4. - DOI
    1. Zucca E, Roggero E, Pinotti G, et al. Patterns of survival in mantle cell lymphoma. Ann Oncol. 1995;6:257–62. - PubMed

LinkOut - more resources